Contrarian picks that promise big profits

Alec Cutler of Orbis Global Balanced Fund finds three stocks ripe with opportunity.

Each week, a professional investor tells us where he'd put his money. This week: Alec Cutler of Orbis GlobalBalanced Fund finds three stocks ripe with opportunity.

Buying cheap stocks and holding onto them for a very long time is a winning investment strategy. While this may sound obvious, investors aren't stupid and cheap stocks are often cheap for a reason.This is the challenge for contrarian investors. In times of extreme negativity, a company might appear uninvestable at any price. Take a closer look, however,and there may be an opportunity investors have missed.

A transformed oil major

The result? BP is now growing production with lower spending, and the barrels from new projects are more profitable than the barrels they replace, resulting in much higher free cash flow. Yet the stock is still priced at a near-6% dividend yield and 14 times consensus earnings for 2019, reflecting ongoing pessimism about the industry.

Take a long-term view of AbbVie

While this blockbuster drug drives considerable earnings and cash flow for AbbVie, the market is concerned about how AbbVie will grow once it loses US patent protection on Humira in 2023. Instead of maximising sales of Humira through to 2023, AbbVie will intentionally cannibalise Humira revenue with its two new drugs, which are proving to be more effective than Humira.

We believe that cannibalising in return for longer patent protection is the right strategy for the long term, but realise that this is likely to make for a bumpy ride in the short to medium term. We are happy to wait. At less than ten times our 2019 earnings estimate and a yield of 5.3%, AbbVie currently has one of the lowest valuations and highest yields in the sector, despite industry-leading earnings growth and one of the most active and promising late-stage drug pipelines.

Investors ignore Bayer's benefits

In addition, the seed business has profited from decades of investment and research into product development, which have made it very difficult for rivals to gain a foothold. Bayer also has a high-quality pharmaceutical business; at eight times consensus earnings for 2019 for the company overall, the market is clearly ignoring that too.

Indeed, we believe the market is overestimating the costs of the Roundup affair. The current price implies the settlement would be more than £700,000 per plaintiff, which is well above the pay-outs for similar suits in the past, and in our opinion highly unlikely.

Recommended

Share tips of the week – 21 January
Share tips

Share tips of the week – 21 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
21 Jan 2022
Seven cheap defence stocks to buy now
Share tips

Seven cheap defence stocks to buy now

We’ve got used to a world without war between major powers, but that era is coming to an end as Russia threatens Ukraine and China eyes Taiwan. Buy de…
21 Jan 2022
HubSpot: a tech stock set to tumble
Trading

HubSpot: a tech stock set to tumble

US tech stocks have had a fantastic couple of years. But this year is unlikely to be so bullish for high-fliers that can’t turn big profits.
18 Jan 2022
Seize these investment trust bargains in 2022
Investment trusts

Seize these investment trust bargains in 2022

Attractive investment trusts are trading at a discount, and those waiting for the perfect time to buy will miss out. Max King picks a selection of the…
17 Jan 2022

Most Popular

Ask for a pay rise – everyone else is
Inflation

Ask for a pay rise – everyone else is

As inflation bites and the labour market remains tight, many of the nation's employees are asking for a pay rise. Merryn Somerset Webb explains why yo…
17 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022
Interest rates might rise faster than expected – what does that mean for your money?
Global Economy

Interest rates might rise faster than expected – what does that mean for your money?

The idea that the US Federal Reserve could raise interest rates much earlier than anticipated has upset the markets. John Stepek explains why, and wha…
6 Jan 2022